M. Maclean

Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT)

Julie Bernhardt, Leonid Churilov, Fiona Ellery et al. · Neurology · 2016 · 217 citations · Full text

Medicine, Rehabilitation Medicine, Geriatric Rehabilitation +14

Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL)

Lyly Le, Holger W. Hirte, Sebastién J. Hotte et al. · Journal of Clinical Oncology · 2004 · 25 citations

Medicine, Oncology, Pharmacology +17

HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial

Sebastién J. Hotte, Holger W. Hirte, E. X. Chen et al. · Journal of Clinical Oncology · 2005 · 19 citations

Life Sciences, Oncology, Pharmacology +17

Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors

Michael A. Carducci, Lillian L. Siu, Rana Sullivan et al. · Journal of Clinical Oncology · 2006 · 11 citations

Medicine, Oncology, Pharmacology +13

A phase I study of the pan-Bcl2 family inhibitor GX15–070, administered as a 3-hour weekly infusion in patients with refractory solid tumors or lymphomas

Kashif Firozvi, Justin H. Hwang, Nora Hansen et al. · Journal of Clinical Oncology · 2006 · 10 citations

Medicine, Oncology, Pharmacology +16